Synthetic biology platform company programming cells for biotechnology, pharmaceuticals, agriculture, and industrial applications.
Profile & Fundamentals
Ginkgo Bioworks: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
Ginkgo Bioworks Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Company profile record
Ginkgo Bioworks Holdings
Common Stock · Health Care · Biotechnology
Company
- Company / asset
- Ginkgo Bioworks Holdings
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Biotechnology
- HQ
- 🇺🇸 United States
- Head office
- 27 Drydock Avenue, Boston, MA, United States, 02210
Leadership & scale
- Chief executive
- Dr. Jason Kelly Ph.D.
- CEO year born
- 1981
- Full-time employees
- 485
- Fiscal year end
- December
- IPO date
- 2021-04-19
Fundamentals snapshot
- Market Cap
- USD 770.6M
- P/E
- --
- Revenue (Q2 26)
- USD 20.2M
- Profit (Q2 26)
- USD -46.7M
- Dividend Yield
- --
- Revenue (FY 25)
- USD 170.2M
- Shares in public float
- 49.9M
- Insider ownership
- 4.43%
Reporting & identifiers
- Symbol
- DNA.NYSE
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US37611X2099
- Asset ID
- equity_d620e41c-a941-50d1-953a-a198ca15eb5f
Ownership
Shares Outstanding
Latest: 62.1M | Max: 62.1M | Min: 29.0M
Latest reported ownership snapshot
As of Oct 1, 2026Float Shares
80.33%
49.9M latest reported shares
Insider Ownership
4.43%
Latest reported insider stake
Short Float
0.13%
Latest reported short interest / float
Top Holders
Source tablesView ownership tables
Shares Outstanding
Annual reported shares outstanding; up to 10 reporting dates.
Scroll the table to see every column.
| Reporting date | Shares outstanding |
|---|---|
| 2019-01-01 | 29,000,000 |
| 2020-01-01 | 32,204,400 |
| 2021-01-01 | 38,288,800 |
| 2022-01-01 | 46,415,200 |
| 2023-01-01 | 50,032,900 |
| 2024-01-01 | 51,894,600 |
| 2025-01-01 | 55,457,700 |
| 2026-01-01 | 62,094,400 |
Top Holders
Available reported ownership records.
Scroll the table to see every column.
| Holder | Shares | Ownership | Reported date |
|---|---|---|---|
| BlackRock Inc | 3,642,347 | 5.41% | 2026-03-31 |
| Viking Global Investors LP | 3,577,128 | 5.31% | 2026-03-31 |
| Baillie Gifford & Co Limited. | 2,391,649 | 3.55% | 2026-06-30 |
| Scottish Mortgage Ord | 2,391,649 | 3.55% | 2026-07-31 |
| Erste Asset Management GmbH | 1,947,728 | 2.89% | 2026-03-31 |
| Vanguard Capital Management, LLC | 1,914,428 | 2.84% | 2026-03-31 |
| Anchorage Advisors, LLC | 1,746,363 | 2.59% | 2026-06-30 |
| Legal & General Group PLC | 1,661,587 | 2.47% | 2026-03-31 |
| L&G Artificial Intelligence ETF | 1,632,208 | 2.42% | 2026-08-31 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1,489,851 | 2.21% | 2026-08-31 |
| State Street Corp | 1,346,659 | 2% | 2026-03-31 |
| iShares Russell 2000 ETF | 1,232,832 | 1.83% | 2026-08-31 |
| Geode Capital Management, LLC | 1,009,362 | 1.5% | 2026-03-31 |
| Forbes J M & Co | 999,911 | 1.48% | 2026-06-30 |
| The Goldman Sachs Group Inc | 929,862 | 1.38% | 2026-03-31 |
Earnings, Profitability & Valuation
Earnings, Profitability & Valuation
Earnings & Revenue
Earnings and Revenue Trajectory
AI Review
The financial trajectory depicts a severe contraction following the post-pandemic runoff and subsequent divestiture of biosecurity testing. In mid-2026, quarterly revenue from continuing operations dropped to approximately $20 million, down nearly half year-over-year. Management attributes this shrinkage to intentional customer program pruning and exiting non-core projects, but operating results demonstrate that the surviving business has not yet achieved commercial scale. Nevertheless, aggressive operational discipline is taking effect. Full-year net losses narrowed significantly from $547 million in 2024 to $313 million in 2025 as research payroll was curtailed. While trailing twelve-month free cash flow remains deeply negative at -$190 million, structural expense reductions provide a viable pathway toward cash-burn containment.
The financial trajectory depicts a severe contraction following the post-pandemic runoff and subsequent divestiture of biosecurity testing. In mid-2026, quarterly revenue from continuing operations dropped to approximately $20 million, down nearly half year-over-year. Management attributes this shrinkage to intentional customer program pruning and exiting non-core projects, but operating results demonstrate that the surviving business has not yet achieved commercial scale. Nevertheless, aggressive operational discipline is taking effect. Full-year net losses narrowed significantly from $547 million in 2024 to $313 million in 2025 as research payroll was curtailed. While trailing twelve-month free cash flow remains deeply negative at -$190 million, structural expense reductions provide a viable pathway toward cash-burn containment.
Revenue, Net Income, and Free Cash Flow
Latest: USD 170.2M | Max: USD 477.7M | Min: USD -2.1B
Valuation
P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.
Latest: --
No history available.
Profitability & Margins
Margins and Operating Efficiency
AI Review
Reported profit margins present a stark economic divergence. Accounting gross margin remained superficially elevated above 80% in 2025, suggesting that direct lab consumable costs are manageable. Yet trailing operating margins sat deeply negative near -185%, exposing an enterprise swamped by fixed overhead. This divergence occurs because extensive automated facilities and platform engineering costs sit within research and administrative overhead rather than cost of sales. Because fixed facility depreciation remains elevated against an $80 million revenue run rate, operating leverage is severely negative. Sustainable profitability requires multi-fold commercial volume growth to absorb fixed carry costs.
Reported profit margins present a stark economic divergence. Accounting gross margin remained superficially elevated above 80% in 2025, suggesting that direct lab consumable costs are manageable. Yet trailing operating margins sat deeply negative near -185%, exposing an enterprise swamped by fixed overhead. This divergence occurs because extensive automated facilities and platform engineering costs sit within research and administrative overhead rather than cost of sales. Because fixed facility depreciation remains elevated against an $80 million revenue run rate, operating leverage is severely negative. Sustainable profitability requires multi-fold commercial volume growth to absorb fixed carry costs.
Profitability Margins
Latest: 81.5% | Max: 100.0% | Min: <-100.0%
Latest Profitability Ratios as of 2025-12-31
Gross Margin
81.5%
Gross profit / revenue
Operating Margin
-185.3%
Operating income / revenue
Net Margin
-183.8%
Net income / revenue
FCF Margin
-105.0%
Free cash flow / revenue
Source tablesView earnings, profitability & valuation tables
Revenue, Net Income, and Free Cash Flow
Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.
Scroll the table to see every column.
| Period end | Revenue (USD) | Net income (USD) | Free cash flow (USD) |
|---|---|---|---|
| 2019-12-31 | 54,184,000 | -119,327,000 | -66,882,000 |
| 2020-12-31 | 76,657,000 | -126,609,000 | -193,651,000 |
| 2021-12-31 | 313,837,000 | -1,830,047,000 | -310,339,000 |
| 2022-12-31 | 477,706,000 | -2,104,929,000 | -304,469,000 |
| 2023-12-31 | 251,455,000 | -892,869,000 | -336,301,000 |
| 2024-12-31 | 227,043,000 | -547,029,000 | -382,126,000 |
| 2025-12-31 | 170,155,000 | -312,763,000 | -178,724,000 |
Published P/E Ratio
Published valuation snapshots retain each observation's earnings basis.
No reported records are available in this preview.
Profitability Margins
Matching annual reporting dates. Values are percentages.
Scroll the table to see every column.
| Period end | Gross margin (%) | Operating margin (%) | Net margin (%) | Free cash flow margin (%) |
|---|---|---|---|---|
| 2019-12-31 | 100 | -132.14 | -220.23 | -123.43 |
| 2020-12-31 | 79.64 | -178.75 | -165.16 | -252.62 |
| 2021-12-31 | 58.68 | -582.62 | -583.12 | -98.89 |
| 2022-12-31 | 57.25 | -462.41 | -440.63 | -63.74 |
| 2023-12-31 | 78.52 | -343.76 | -355.08 | -133.74 |
| 2024-12-31 | 83.02 | -246.54 | -240.94 | -168.31 |
| 2025-12-31 | 81.48 | -185.29 | -183.81 | -105.04 |
Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Source: eodhd. Snapshot retrieved 2026-09-29.
Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.